ABSTRACT
Polymers have attracted attention as luminophores due to their excellent electrochemiluminescence (ECL) properties. However, the current research and application of polymers mainly focus on anode emission, and ECL efficiency is not high enough, thus showing a limited application. This work exploited the persulfate-mediated dual-emission characteristics of poly[2,5-dioctyl-1,4-phenylene] polymer nanoparticles (PDP PNPs). The two ECL emissions were collected synchronously at -2.0V and +1.0V with persulfate (S2O82-) as cathodic coreactant and 3-(dibutylamino) propylamine (TDBA) as anodic coreactant, respectively. Interestingly, S2O82- can simultaneously mediate the double emissions, significantly enhancing both cathode emission and anode emission. The dual-emission mechanism was explored carefully and enhancement mechanism of cathodic coreactant S2O82- to anodic emission was hypothesized to be attributed to SO4∙− radicals, which was produced from S2O82- during cathodic potential scanning and oxidized PDP PNPs to generate more cation radical, thus enhancing anodic emission of PDP PNPs. Moreover, the black hole quencher-2 (BHQ2) was exploited as dual-function moderator to quench dual emissions of PDP PNPs synchronously. PDP PNPs coupled with BHQ2 to build ECL ratiometric system for detecting SARS-CoV-2 RdRp gene and its limit of detection was 25.1 aM. Persulfate-mediated double emissions provided a new way to improve the efficiency of ECL emission from polymers and expand their application. The clever integration of dual-emitting PDP PNPs and dual-regulating BHQ2 created a promising single-luminophore-based ratiometric ECL platform, developed an attractive ECL method for detecting SARS-CoV-2 RdRp gene.
ABSTRACT
The global effort against the COVID-19 pandemic dictates that routine quantitative detection of SARS-CoV-2 neutralizing antibodies is vital for assessing immunity following periodic revaccination against new viral variants. Here, we report a dual-detection fluorescent immunochromatographic assay (DFIA), with a built-in self-calibration process, that enables rapid quantitative detection of neutralizing antibodies that block binding between the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and the angiotensin-converting enzyme 2 (ACE2). Thus, this assay is based on the inhibition of binding between ACE2 and the RBD of the SARS-CoV-2 spike protein by neutralizing antibodies, and the affinity of anti-human immunoglobulins for these neutralizing antibodies. Our self-calibrating DFIA shows improved precision and sensitivity with a wider dynamic linear range, due to the incorporation of a ratiometric algorithm of two-reverse linkage signals responding to an analyte. This was evident by the fact that no positive results (0/14) were observed in verified negative samples, while 22 positives were detected in 23 samples from verified convalescent plasma. A comparative analysis of the ability to detect neutralizing antibodies in 266 clinical serum samples including those from vaccine recipients, indicated that the overall percent agreement between DFIA and the commercial ELISA kit was 90.98%. Thus, the proposed DFIA provides a more reliable and accurate rapid test for detecting SARS-CoV-2 infections and vaccinations in the community. Therefore, the DFIA based strategy for detecting biomarkers, which uses a ratiometric algorithm based on affinity and inhibition reactions, may be applied to improve the performance of immunochromatographic assays.